GRFS
Price
$10.13
Change
+$0.23 (+2.32%)
Updated
Sep 5 closing price
Capitalization
8.66B
60 days until earnings call
PFE
Price
$24.88
Change
+$0.34 (+1.39%)
Updated
Sep 5 closing price
Capitalization
141.46B
58 days until earnings call
Interact to see
Advertisement

GRFS vs PFE

Header iconGRFS vs PFE Comparison
Open Charts GRFS vs PFEBanner chart's image
Grifols SA
Price$10.13
Change+$0.23 (+2.32%)
Volume$424K
Capitalization8.66B
Pfizer
Price$24.88
Change+$0.34 (+1.39%)
Volume$34.61M
Capitalization141.46B
GRFS vs PFE Comparison Chart in %
Loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRFS vs. PFE commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRFS is a StrongBuy and PFE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (GRFS: $10.13 vs. PFE: $24.88)
Brand notoriety: GRFS: Not notable vs. PFE: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GRFS: 41% vs. PFE: 85%
Market capitalization -- GRFS: $8.66B vs. PFE: $141.46B
GRFS [@Pharmaceuticals: Major] is valued at $8.66B. PFE’s [@Pharmaceuticals: Major] market capitalization is $141.46B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $651.91B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRFS’s FA Score shows that 1 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • GRFS’s FA Score: 1 green, 4 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, GRFS is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRFS’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 6 bullish TA indicator(s).

  • GRFS’s TA Score: 6 bullish, 3 bearish.
  • PFE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GRFS is a better buy in the short-term than PFE.

Price Growth

GRFS (@Pharmaceuticals: Major) experienced а +1.60% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.48% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.16%. For the same industry, the average monthly price growth was +3.97%, and the average quarterly price growth was +10.41%.

Reported Earning Dates

GRFS is expected to report earnings on Nov 06, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.16% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($141B) has a higher market cap than GRFS($8.66B). GRFS has higher P/E ratio than PFE: GRFS (19.75) vs PFE (13.16). GRFS YTD gains are higher at: 38.452 vs. PFE (-1.174). PFE has higher annual earnings (EBITDA): 20.2B vs. GRFS (1.62B). PFE has higher revenues than GRFS: PFE (63.8B) vs GRFS (7.45B).
GRFSPFEGRFS / PFE
Capitalization8.66B141B6%
EBITDA1.62B20.2B8%
Gain YTD38.452-1.174-3,275%
P/E Ratio19.7513.16150%
Revenue7.45B63.8B12%
Total CashN/A13.2B-
Total DebtN/A60.9B-
FUNDAMENTALS RATINGS
GRFS vs PFE: Fundamental Ratings
GRFS
PFE
OUTLOOK RATING
1..100
8526
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8462
PRICE GROWTH RATING
1..100
4955
P/E GROWTH RATING
1..100
9197
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as GRFS (21). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GRFS (100). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's SMR Rating (62) in the Pharmaceuticals Major industry is in the same range as GRFS (84). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

GRFS's Price Growth Rating (49) in the Pharmaceuticals Major industry is in the same range as PFE (55). This means that GRFS’s stock grew similarly to PFE’s over the last 12 months.

GRFS's P/E Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as PFE (97). This means that GRFS’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRFSPFE
RSI
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
47%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
49%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
51%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
54%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 6 days ago
57%
Declines
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 4 days ago
59%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 6 days ago
58%
Aroon
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
52%
View a ticker or compare two or three
Interact to see
Advertisement
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BSCX21.530.09
+0.42%
Invesco BulletShares 2033 Corp Bd ETF
IJAN34.870.11
+0.33%
Innovator Itnl Dvp Pwr Buff ETF™ Jan
RMNY23.83N/A
N/A
Rockefeller New York Municipal Bond ETF
SPMO117.05-0.28
-0.24%
Invesco S&P 500® Momentum ETF
OILU22.61-1.17
-4.92%
MicroSectorsTM Oil&Gs Exp&Pd 3X Lvg ETNs

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+2.32%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
PFE - GRFS
28%
Poorly correlated
+1.39%
BIIB - GRFS
28%
Poorly correlated
+0.52%
GILD - GRFS
26%
Poorly correlated
+2.02%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been loosely correlated with GSK. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
+1.39%
GSK - PFE
57%
Loosely correlated
+2.25%
NVS - PFE
57%
Loosely correlated
+1.02%
BIIB - PFE
56%
Loosely correlated
+0.52%
ABBV - PFE
53%
Loosely correlated
-0.21%
BMY - PFE
53%
Loosely correlated
+0.96%
More